APA (7th ed.) Citation

Z, L., K, L., X, Z., JL, A., S, L., C, B., . . . N, P. (2023). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): An analysis of a prospective multicentre cohort study. The lancet. Gastroenterology & hepatology, 8(2), 145. https://doi.org/10.1016/S2468-1253(22)00389-2

Chicago Style (17th ed.) Citation

Z, Liu, et al. "Neutralising Antibody Potency Against SARS-CoV-2 Wild-type and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease Treated with Infliximab and Vedolizumab After Three Doses of COVID-19 Vaccine (CLARITY IBD): An Analysis of a Prospective Multicentre Cohort Study." The Lancet. Gastroenterology & Hepatology 8, no. 2 (2023): 145. https://doi.org/10.1016/S2468-1253(22)00389-2.

MLA (9th ed.) Citation

Z, Liu, et al. "Neutralising Antibody Potency Against SARS-CoV-2 Wild-type and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease Treated with Infliximab and Vedolizumab After Three Doses of COVID-19 Vaccine (CLARITY IBD): An Analysis of a Prospective Multicentre Cohort Study." The Lancet. Gastroenterology & Hepatology, vol. 8, no. 2, 2023, p. 145, https://doi.org/10.1016/S2468-1253(22)00389-2.